| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. | 6.2% | +20% | $1,345,504 | +$212,929 | 596,068 | +19% | Anders Hove | 06 Jan 2026 |
| Oliveira Steven Michael | 4.1% | -20% | $69,324 | -$788,375 | 161,218 | -92% | Oliveira Steven Michael | 01 Oct 2025 |
As of 30 Sep 2025, 2 institutional investors reported holding 1,052 shares of Athira Pharma, Inc. - Common Stock, $0.0001 Par Value (ATHA). This represents 0.01% of the company’s total 9,614,000 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 1,052 | $595 | -$5,287,813 | $2.26 | 2 |
| 2025 Q2 | 17,548,824 | $5,295,638 | -$4,949 | $0.30 | 50 |
| 2025 Q1 | 17,565,344 | $5,002,785 | -$111,724 | $0.28 | 52 |
| 2024 Q4 | 17,941,214 | $10,513,004 | +$1,178,843 | $0.59 | 54 |
| 2024 Q3 | 16,127,283 | $7,192,349 | -$16,853,433 | $0.45 | 57 |
| 2024 Q2 | 22,193,550 | $58,807,500 | +$1,293,365 | $2.65 | 65 |
| 2024 Q1 | 21,695,406 | $59,443,068 | -$97,736 | $2.74 | 73 |
| 2023 Q4 | 21,901,553 | $53,218,137 | -$1,803,042 | $2.43 | 64 |
| 2023 Q3 | 21,432,485 | $43,293,241 | -$1,350,548 | $2.02 | 70 |
| 2023 Q2 | 21,887,052 | $64,565,221 | -$5,342,980 | $2.95 | 75 |
| 2023 Q1 | 23,800,339 | $59,499,805 | -$1,181,241 | $2.50 | 81 |
| 2022 Q4 | 21,723,717 | $68,861,491 | +$2,742,172 | $3.17 | 88 |
| 2022 Q3 | 19,427,390 | $57,700,388 | -$235,989 | $2.97 | 91 |
| 2022 Q2 | 19,112,511 | $58,288,232 | -$99,335,925 | $3.05 | 84 |
| 2022 Q1 | 25,755,755 | $347,589,678 | -$1,417,397 | $13.50 | 98 |
| 2021 Q4 | 26,187,732 | $341,201,519 | +$17,586,336 | $13.03 | 95 |
| 2021 Q3 | 24,890,216 | $233,607,844 | +$136,252 | $9.38 | 91 |
| 2021 Q2 | 24,736,986 | $253,318,555 | -$61,368,215 | $10.24 | 86 |
| 2021 Q1 | 26,338,868 | $484,403,324 | +$83,801,125 | $18.40 | 68 |
| 2020 Q4 | 21,510,354 | $733,206,641 | +$28,950,630 | $34.25 | 69 |
| 2020 Q3 | 21,658,200 | $395,426,446 | +$395,426,626 | $18.46 | 54 |